全球制药企业在专利到期前纷纷削减成本,正加大力度寻找中国研发的创新候选药物,行业分析师预计,今年相关授权交易规模将飙升至历史新高。据医药数据平台药魔方(Pharmcube)统计,大中华区(含香港、澳门、台湾)企业签署的此类交易总金额,在 2025 年较 2021 年飙升近10 倍,达到1377 亿美元的空前水平。中国大陆是这一浪潮的绝对核心。诺华、默克、葛兰素史克等全球药企均在去年签下重磅合作协议...
Source Link全球制药企业在专利到期前纷纷削减成本,正加大力度寻找中国研发的创新候选药物,行业分析师预计,今年相关授权交易规模将飙升至历史新高。据医药数据平台药魔方(Pharmcube)统计,大中华区(含香港、澳门、台湾)企业签署的此类交易总金额,在 2025 年较 2021 年飙升近10 倍,达到1377 亿美元的空前水平。中国大陆是这一浪潮的绝对核心。诺华、默克、葛兰素史克等全球药企均在去年签下重磅合作协议...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.